Crossmark

A Response to: Letter to the Editor Regarding “Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults”

Crossref DOI link: https://doi.org/10.1007/s40121-024-01039-5

Published Online: 2024-09-18

Published Print: 2024-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Georgieva, Mihaela

Sun, Tianyu

Beck, Ekkehard
License Information

Text and Data Mining valid from 2024-09-18

Version of Record valid from 2024-09-18
More Information

Article History

Received: 7 August 2024

Accepted: 28 August 2024

First Online: 18 September 2024

Declarations

:

: Mihaela Georgieva, Tianyu Sun, and Ekkehard Beck are employees of Moderna, Inc. may hold stock/stock options in the company.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Document is current

Any future updates will be listed below